- $2.73bn
- $2.50bn
- $4.09m
U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley
AtaiBeckley rises as depression drug moves toward late‑stage trials
Brief: AtaiBeckley Files For Mixed Shelf Offering
Brief: AtaiBeckley Is Said To Explore Options For Main Psychedelic Drug- Bloomberg News
Brief: Atai Life Sciences Q4 Operating Expenses USD 571.048 Million
AtaiBeckley's Q4 loss widens on merger-related R&D costs
Brief: Ataibeckley Announces Successful End-Of-Phase 2 Meeting For Bpl-003 In Treatment-Resistant Depression
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America
U.S. STOCKS ON THE MOVE-Qnity, J.M. Smucker, Vistra
AtaiBeckley rises as experimental pill shows early benefit for social anxiety
Brief: Ataibeckley Appoints Michael Faerm As Chief Financial Officer
Advisory: Alerts incorrectly tagged to Atai Beckley NV withdrawn
Atai Life Sciences rises after $130 mln equity offering
Brief: Atai Life Sciences NV Prices Offering Of 23.7 Million Shares At $5.48 Per Share
Brief: ATAI Life Sciences NV Files For Potential Mixed Shelf - SEC Filing
Atai Life Sciences schizophrenia drug fails to meet main goal in trial (updated)
Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial
Brief: Recognify Life Sciences Says Schizophrenia Drug Fails To Meet Main Goal In Trial
Brief: Atai Life Sciences Announces $50 Million Private Placement Financing